{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [
    [
      "CAR T cells",
      "Cancer immunotherapy",
      "cancer cells",
      "hematologic malignancies",
      "leukemia",
      "solid tumor."
    ]
  ],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "29676233",
  "DateCompleted": {
    "Year": "2018",
    "Month": "11",
    "Day": "23"
  },
  "DateRevised": {
    "Year": "2018",
    "Month": "11",
    "Day": "23"
  },
  "Article": {
    "ArticleDate": [],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "10.2174/1574888X13666180420110239"
    ],
    "Journal": {
      "ISSN": "2212-3946",
      "JournalIssue": {
        "Volume": "13",
        "Issue": "5",
        "PubDate": {
          "Year": "2018"
        }
      },
      "Title": "Current stem cell research & therapy",
      "ISOAbbreviation": "Curr Stem Cell Res Ther"
    },
    "ArticleTitle": "Chimeric Antigen Receptor T Cell Based Immunotherapy for Cancer.",
    "Pagination": {
      "StartPage": "327",
      "EndPage": "335",
      "MedlinePgn": "327-335"
    },
    "Abstract": {
      "AbstractText": [
        "Cancer immunotherapy, a new weapon against cancers by harnessing the patient's own immune system, potentiates an extended remission and possibly a cure for cancer. T cells genetically engineered with chimeric antigen receptor (CAR) vectors can specifically target the surface antigen of cancer cells and kill them in an MHC-independent manner. CD19 is extensively expressed on cancerous cells in B cell malignancies. To target this antigen, CAR T cells have gained great success in treating patients with B cell leukemia and lymphoma. Currently, the data from clinical trials on CAR T cells in solid tumors are limited; thus, CAR T cells targeting GD2, HER2, EGFRvIII, CSPG4, DNAX, mesothelin, and other molecules are under active investigation for solid tumors. In this review, we summarize the clinical results for CAR T cells in the case of hematologic and solid tumors, along with the current developments in CAR T cell immunotherapy."
      ],
      "CopyrightInformation": "Copyright\u00a9 Bentham Science Publishers; For any queries, please email at epub@benthamscience.org."
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Biotherapy Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China."
          }
        ],
        "LastName": "Li",
        "ForeName": "Feng",
        "Initials": "F"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Biotherapy Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China."
          },
          {
            "Identifier": [],
            "Affiliation": "Department of Hematology and Oncology, Harvard Medical School, Boston, MA, United States."
          }
        ],
        "LastName": "Zhang",
        "ForeName": "Tengfei",
        "Initials": "T"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Biotherapy Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China."
          }
        ],
        "LastName": "Cao",
        "ForeName": "Ling",
        "Initials": "L"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Biotherapy Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China."
          },
          {
            "Identifier": [],
            "Affiliation": "Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China."
          },
          {
            "Identifier": [],
            "Affiliation": "Engineering Key Laboratory for Cell Therapy of Henan Province, Zhengzhou, Henan, China."
          },
          {
            "Identifier": [],
            "Affiliation": "School of Life Sciences, Zhengzhou University, Zhengzhou, Henan, China."
          }
        ],
        "LastName": "Zhang",
        "ForeName": "Yi",
        "Initials": "Y"
      }
    ],
    "PublicationTypeList": [
      "Journal Article",
      "Review"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "United Arab Emirates",
    "MedlineTA": "Curr Stem Cell Res Ther",
    "NlmUniqueID": "101272517",
    "ISSNLinking": "1574-888X"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Antigens, CD19"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Antigens, Neoplasm"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Receptors, Antigen, T-Cell"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Recombinant Fusion Proteins"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [
        "immunology"
      ],
      "DescriptorName": "Antigens, CD19"
    },
    {
      "QualifierName": [
        "immunology"
      ],
      "DescriptorName": "Antigens, Neoplasm"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [
        "adverse effects",
        "trends"
      ],
      "DescriptorName": "Immunotherapy, Adoptive"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Models, Biological"
    },
    {
      "QualifierName": [
        "immunology",
        "therapy"
      ],
      "DescriptorName": "Neoplasms"
    },
    {
      "QualifierName": [
        "immunology"
      ],
      "DescriptorName": "Receptors, Antigen, T-Cell"
    },
    {
      "QualifierName": [
        "immunology"
      ],
      "DescriptorName": "Recombinant Fusion Proteins"
    },
    {
      "QualifierName": [
        "immunology",
        "transplantation"
      ],
      "DescriptorName": "T-Lymphocytes"
    }
  ]
}